; (ii) the typical times each day the veteran self-administers; (iii) the frequency of different products per day and for what condition, symptom, or both; and (iv) the amounts per product. (F) The ratings and descriptions of the effectiveness of using cannabis to treat conditions, symptoms, or both. (G) Any experiences with side effects. (H) The number of different cannabis products tried before settling on the current product. (I) The typical source of medical cannabis (such as a single dispensary, multiple dispensaries, mail order, or other source), the typical purchase frequency, and the typical amount purchased. (J) The sources of information the veteran uses for products and dosages. (K) Factors that influence the choice of the veteran for using a chosen product (such as with respect to the levels of tet­ra­hy­dro­can­nab­i­nol or cannabidiol content, cost, availability, consistency, or strain). (L) Any other matters determined appropriate. (2) Health care providers The survey described in subsection (c)(2) shall cover the following subjects: (A) A description of the experience of the health care provider with respect to patents using medicinal cannabis. (B) A description by the health care provider of how medicinal cannabis is changing patients. (C) A description of how treatment plans have been modified after a veteran discloses using cannabis. (D) Any documentation of the products, dosages, or frequency of such cannabis use in the medical records of the veteran. (E) Reporting of adverse events. (F) The sources of information used by the health care provider with respect to cannabis products and the medical effectiveness of cannabis. (G) Any other matters determined appropriate. (e) Report Not later than one year after the date of the enactment of this Act, the Secretary shall submit to the Committees on Veterans’ Affairs of the Senate and House of Representatives a report on the results of the surveys conducted under this section.